Saturday - September 13, 2025
European Society of Cardiology: Aficamten is Superior to Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
August 30, 2025
SOPHIA ANTIPOLIS, France, Aug. 30 -- The European Society of Cardiology issued the following news release:

* * *

Aficamten is superior to metoprolol for symptomatic obstructive hypertrophic cardiomyopathy

* Beta-blockers are commonly used in the initial treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM), despite limited evidence of their efficacy.

* The MAPLE-HCM trial compared the cardiac myosin inhibitor, aficamten, with . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products